Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 227-563-7 | CAS number: 5888-87-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- As none of the deviations were rated as critical, deviation notes were not issued. The study report reflects the deviations in an appropriate way.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- N,N'-hexane-1,6-diylbis(hexahydro-2-oxo-1H-azepine-1-carboxamide)
- EC Number:
- 227-563-7
- EC Name:
- N,N'-hexane-1,6-diylbis(hexahydro-2-oxo-1H-azepine-1-carboxamide)
- Cas Number:
- 5888-87-9
- Molecular formula:
- C20H34N4O4
- IUPAC Name:
- N,N'-hexane-1,6-diylbis(2-oxoazepane-1-carboxamide)
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): N,N'-hexane-1 ,6-diylbis(hexahydro-2-oxo-1 H-azepine-1-carboxamide)
- Substance type: organic substance
- Physical state: solid
- Analytical purity: 100%
- Lot/batch No.: 07112601
- Storage condition of test material: Room temperature (20°C ± 5°C), dry
- Other:
The test item arrived at NewLab BioQuality GmbH on 07 January 2008 at ambient
temperature and was stored at room temperature on a cJosed shelf upon arrival. Additional
test item of the same batch arrived at NewLab BioQuality GmbH on 11 March 2008 at
ambient temperature and was stored at room temperature on a closed shelf upon arrival.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkel mann GmbH, Gartenstraße 27, 33178 Borehen, Germany
- Age at study initiation: 5 - 8 weeks
- Weight at study initiation: males: 167 to 175 grams (mean), females: 151 to 159 grams (mean)
- Fasting period before study: no
- Housing: Clean conventional housing: aeration with approx. 10 air changes per hour, room climate 22 ± 3°C at 30-70% relative humidity, artificial lighting , 12 h Iight / 12 h dark
Eight groups of five animals each in open makroion cages type 2000P (TechniPlast)
Lignocel hygienic animal bedding (J. Rettenmaier & Söhne GmbH + Co. KG, 73494 Rosenberg)
- Diet (e.g. ad libitum): Maintenance diet rat/mouse, pellets, No. 1324 (Altromin GmbH & Co. KG, 32791 Lage), ad /ib.
- Water (e.g. ad libitum): Autoclaved community tap water, ad lib.
- Acclimation period: 8 days (male) / 9 days (female)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3°C
- Humidity (%): 30-70% relative humidity
- Air changes (per hr): 10 air changes per hour
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): daily
- Mixing appropriate amounts with (Type of food): corn oil
VEHICLE
- Justification for use and choice of vehicle (if other than water): test item has low solubility in water
- Amount of vehicle (if gavage): The test solutions were intended for an application volume of 8 ml per kg body weight. - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Prior to this study, an acute oral toxicity study according to OECD 401 was performed in rats, which resulted in an LD50 of more than 2000 mg/kg body weight.
In a previously performed dose range finding study with dose escalation, the test item was administered in doses up to 2000 mg/kg body weight over a time period of 19 days and produced no observable toxic effects in the test animals. For this study, a high dose of 1000 mg/kg body weight was determined on request of the sponsor.
- Rationale for animal assignment (if not random):
On the day of arrival, the animals were caged in groups of five according to the following
stratification protocol: rats were weighed individually and grouped into weight categories, the
main group consisting of animals weighing between 100 g and 120 g. These were placed
consecutively into prepared cages. Rats weighing more than 120 g, but not more than 140 g,
were caged similarly after the main weight group was placed. At the time point of
stratification, no rat weighed less than 100 g or more than 120 g. - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Viability/fatalities: Daily
- General clinical signs/behaviour: Once workdays
Cage-side observations to detect signs of illness, reactions to treatment, moribundity, or
mortality were performed at least once daily throughout the study, up to the day of necropsy.
Data were recorded on checklists. In ca se of any findings, the individual animal was
examined by use of an extra "health status" form sheet.
DETAILED CLINICAL OBSERVATIONS: Yes
Once weekly (including once before beginning of application)
Individual monitoring of detailed clinical signs was performed once before the first
application, and once a week thereafter. Findings were noted on prepared checklists,
comprising:
-changes in skin, fur, eyes, mucous membranes
-occurrence of secretions and excretions
-autonomie activity (e .g. lacrimation, piloerection, unusual respiratory patterns)
-changes in gait, posture, and response to handling
-presence of clonic or tonic movements, stereotypies (e.g. excessive grooming,
repetitive circling) , bizarre behaviour (e.g. self-mutilation, walking backwards)
-and any other observed, unusual signs.
BODY WEIGHT: Yes
- Time schedule for examinations:
Once weekly (including once before beginning of application)
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
Individual body weight and group food intake was monitored on a weekly basis, group water intake was monitored semiweekly during the in Iife phase, including day 1.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: weekly
- Dose groups that were examined: all
HAEMATOLOGY: Yes
- Time schedule for collection of blood: day 29
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: all
- Parameters checked in table below were examined:
Leukocytes
Erythrocytes
Reticulocytes
Hemoglobin concentration (HB)
Hematocrit (HKT)
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin conc. (MCHC)
Sodium
Potassium
Chloride
Calcium
Glucose (in serum)
Total cholesterol
Urea
Creatinine
Platelets/thrombocytes
Lymphocytes
Monocytes
Band neutrophils
Segmented neutrophils
Eosinophils
Basophils
Total protein
Albumin (in serum)
Globulin
Albumin/Globulin Ratio
Alanine aminotransterase (ALT)
Aspartate aminotransterase (AST)
Alkaline phosphatase
Gamma glutamyl transterase (GGT)
CLINICAL CHEMISTRY: Yes
see under "HEMATOLOGY"
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once before application and once during the last
exposure week
- Dose groups that were examined: all
- Battery of functions tested:
On day 1 and in the last exposure week, additional recordings were made of grip strength
and reactivity to stimuli (Iimb placing test). - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table)
The weight of organs denoted by "W" in was recorded; tissues denoted by "P" were preserved in the appropriate fixatives.
1 Gross lesions P
2 Oesophagus P
3 Trachea and thyroid P
4 Stomach P
5 Thymus P, W
6 Liver P, W
7 Spleen P,W
8 Duodenum P
9 Jejunum P
10 Ileum (with Peyer's patches)
11 Cecum P
12 Adrenals P,W
13 Urinary bladder P
14 Testes/ovary P,W
15 Epididymides P,W
16 Prostate/uterus P
17 Heart P, W
18 Lungs P
19 Peripheral nerve P
20 Bane marrow P
21 Sternum P
22 Spinal cord P
23 Colon P
24 Rectum P
25 Lymph nodes (intestinal area)
26 Kidney P,W
27 Whole brain W
28 Cerebrum P
29 Cerebellum P
30 Pans P
HISTOPATHOLOGY: Yes
Histological preparation was performed of the organs and tissues denoted by "P" in the table above.
The selected tissues were embedded in paraffin wax, sectioned, and stained with hemalaum
and eosin. The stained sections were transferred to the principal investigator 2 for
histopathological examination. The results were returned in a pathology expert report to the
hands of the study director.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- In the course of this study, no signs of illness (e.g. changes in skin, secretions), autonomic activity (e.g. lacrimation, piloerection), stereotypies, or behavioural reactions (e.g. selfmutilation) in response to the treatment or otherwise was observed.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- In the course of this study, no signs of illness (e.g. changes in skin, secretions), autonomic activity (e.g. lacrimation, piloerection), stereotypies, or behavioural reactions (e.g. selfmutilation) in response to the treatment or otherwise was observed.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The weight increase of the male and female animals from all animal groups was within normal range for rats of this strain and age.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The food consumption of all animals was within normal range for rats of this strain and age.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- The water consumption of all animals was within normal range for rats of this strain and age.
- Ophthalmological findings:
- effects observed, treatment-related
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No abnormalities in the general clinical signs or the behaviour were observed.
No animal of the test item groups or the vehicle groups died during the in-life phase of this
study.
In the course of this study, no signs of illness (e.g. changes in skin, secretions), autonomic
activity (e.g. lacrimation, piloerection), stereotypies, or behavioural reactions (e.g. selfmutilation)
in response to the treatment or otherwise was observed.
BODY WEIGHT AND WEIGHT GAIN
The weight increase of the male and female animals from all animal groups was within
normal range for rats of this strain and age. The weight gain of
male rats that received the high dose of the test item was slightly but significantly lower than
the control group during the fourth week of the study.
The low dose group of the female animals showed a similar weight gain when compared to
the vehicle group, animals from the medium and high dose groups gained significantly more
weight during the course of the study.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
The food consumption of all animals was within normal range for rats of this strain and age.
FOOD EFFICIENCY
no data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
The water consumption of all animals was within normal range for rats of this strain and age.
OPHTHALMOSCOPIC EXAMINATION
yes
HAEMATOLOGY
Analysis of hematology and serum biochemistry showed normal results in most instances.
The blood parameters of male animals treated with the test
item showed erratic and few significant alterations when compared to the vehicle control
group. Chloride and the blood clotting time were slightly raised in the high dose group. In the
medium dose group, MCHC was slightly raised and reticulocytes and Albumin was slightly
lowered in comparison to their control group. The low dose group showed slightly elevated
numbers of segmented neutrophiles and a slightly decreased number of Iymphocytes. All
parameters measured in the blood of the male animals were without pathological findings.
The most prominent effects of the females of the high dose group and the medium dose
group were a significantly raised level of cholesterol and of globulin, indicating liver stress.
The raised levels of total protein and of the albumin/globulin ratio of the high dose group and,
milder, in the medium dose group when compared to the vehicle control group also point to
the liver as main target of the test item. A slight increase of monocytes and leucocytes was
restricted to the female high dose group and possibly indicates a mild effect of liver stress.
Although some significant changes were observed, none of the observed average data
points were overall extremely out of range for rats of this strain and age. Other biochemical
parameters and the blood cell counts showed no significant differences among the groups.
URINALYSIS
no data available
NEUROBEHAVIOUR
Motor activity and reactivity to visual and proprioceptive stimuli were not altered by the
administration of the test item. At the end of the observation
period, no differences in grip strength were observed in relation to the vehicle control group,
and none of the animals showed significant differences to the vehicle group during the limb
placing test.
ORGAN WEIGHTS
The organ weights of the male animals of the test item groups showed no difference to those
of the vehicle group. In the female dose groups, a significant increase in liver weight was
noted in the high dose group.
HISTOPATHOLOGY: NON-NEOPLASTIC
At histopathologic examination, a small number of microscopic findings were recorded in the
organs examined in this study. The type, incidence, and severity of almost all microscopic
findings noted did not indicate a relationship to the treatment with the test item.
In the liver, aminimal, centrilobular hepatocellular hypertrophy was observed in all males and
4 of the 5 females of the high dose group.
All other alterations were regarded to be spontaneous in nature and within the normal
background pathology commonly seen in rats of this strain and age.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed until 1000 mg/kg bw/day
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
The following table summarises the results of the treatment groups compared to the vehicle control group:
Parameter | Females | Males | ||||
Low dose | Medium dose | High dose | Low dose | Medium dose | High dose | |
Detailed clinical signs | NAD | NAD | NAD | NAD | NAD | NAD |
Body weight | NAD | elevated | elevated | NAD | NAD | NAD |
Food consumption | NAD | NAD | NAD | NAD | NAD | NAD |
Water consumption | NAD | NAD | NAD | NAD | NAD | NAD |
Grip strength | NAD | NAD | NAD | NAD | NAD | NAD |
Limb placing test | NAD | NAD | NAD | NAD | NAD | NAD |
Hematology | NAD | cholesterol and globulin elevated | cholesterol and globulin elevated | NAD | NAD | NAD |
Necropsy | NAD | NAD | NAD | NAD | NAD | NAD |
Organ weights | NAD | NAD | liver weight increased | NAD | NAD | NAD |
Histology | n.e. | n.e. | hepatoeellular hypertrophy | n.e. | n.e. | hepatoeellular hypertrophY |
NAD: No abnormality detected
n.e.: not examined
Applicant's summary and conclusion
- Conclusions:
- General and detailed clinical signs, food and water consumption, and motor activity and
reactivity to sensory stimuli showed no abnormalities.
The weight gain of male animals was within normal range. The low dose group of the female
animals showed no difference in comparison to the vehicle group, the medium and high dose
groups gained mildly but significantly more weight during the course of the study.
Hematology and serum biochemistry parameters measured in the blood of the male animals
treated with the test item were not altered in comparison to their reference group. In
comparison to the vehicle control group, blood cholesterol and globulin levels were higher in
female rats of the high dose and of the medium dose groups. Other parameters were not
altered.
At macroscopic examination, no pathological findings were observed. The organ weights of
the male animals of the test item groups showed no difference to those of the vehicle group.
In the female high dose group, a significant increase in liver weight was noted.
Histopathological examination revealed aminimal, centrilobular hepatocellular hypertrophy in
the livers of all males and most females of the high dose groups.
The repeated daily oral administration of N,N'-hexane-1 ,5-diylbis(hexahydro-2-oxo-1 Hazepine-
1-carboxamide) to Wistar-Unilever rats at dose levels of 1000, 250, and 63 mg/kg
bodyweight for a treatment period of 28 days produced mild treatment-related alterations in
the liver of the high dose groups.
Microscopically, a minimal hepatocellular hypertrophy was noted in the liver of all male and
most female animals of the high dose group. A large number of medicinal agents with
different chemical structures and therapeutic activities produce liver enlargement when given
in high doses to species used in toxicity studies. Findings of this nature are in favour of an
adaptive response rather than a direct toxic effect of the test item. This finding, not present in
the control animals, was considered to be related to the treatment with the test item. - Executive summary:
The repeated daily oral administration of N,N'-hexane-1 ,6-diylbis(hexahydro-2-oxo-1H-azepine-
1-carboxamide) to Wistar-Unilever rats at dose levels of 1000, 250, and 63 mg/kg
bodyweight for a treatment period of 28 days produced mild treatment-related alterations in
the liver of the high dose groups.
Microscopically, a minimal hepatocellular hypertrophy was noted in the liver of all male and
most female animals of the high dose group. A large number of medicinal agents with
different chemical structures and therapeutic activities produce liver enlargement when given
in high doses to species used in toxicity studies . Findings of this nature are in favour of an
adaptive response rather than a direct toxic effect of the test item. This finding, not present in
the control animals, was considered to be related to the treatment with the test item.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
